Biogen intends to increase stake in Samsung Bioepis

Samsung BioLogics Co. Ltd. (KSE:207940) said it received a letter from partner Biogen Inc. (NASDAQ:BIIB) in which the biotech said it intends to exercise its option to increase its stake in Samsung Bioepis, a JV between Samsung BioLogics and Biogen. Samsung BioLogics disclosed the news in a May 17 regulatory filing. Biogen's option would increase its stake to 50% from 5%.

Samsung Bioepis launched in 2012 to develop biosimilars and has since expanded its focus to discover, develop and commercialize novel biologics (see BioCentury, Sept. 1, 2017)...